Product logins

Find logins to all Clarivate products below.


Novartis | Gastrointestinal | Strategy and Drivers | 2024

The Company Franchise Analysis (CFA) provides a comprehensive evaluation of the franchise, including benchmarking, strategic insights, and an overview of marketed products. It highlights key market drivers and offers a detailed pipeline and sales analysis, along with information on deals and significant events. This profile aims to deliver a thorough understanding of the market dynamics and the strategic positioning of the franchise’s drugs.

Related Market Assessment Reports

Report
Crohn’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics / targeted oral therapies. The well-established TNF-alpha…
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Ulcerative Colitis – Landscape & Forecast – Disease Landscape & Forecast (G7)
We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…
Report
Ulcerative Colitis – Epidemiology – Epidemiology – Ulcerative Colitis – Mature Markets
Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Report
Eosinophilic Esophagitis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of eosinophilic esophagitis (EoE) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States…